Triple threat: new Pre-Surgery combo targets stomach cancer
NCT ID NCT07182565
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether giving a shorter course of radiation (hypofractionated radiotherapy) along with immunotherapy (serplulimab) and chemotherapy before surgery can safely improve outcomes for people with gastroesophageal junction cancer. The trial will enroll 84 participants with locally advanced but resectable disease. The goal is to find the best radiation dose and see how many patients have no cancer left at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hypofractionated radiotherapy, serplulimab (PD-1 inhibitor), paclitaxel, and TS-1
What this could lead to
If successful, this could offer a more effective pre-surgery treatment for gastroesophageal junction cancer, potentially increasing the chance of complete tumor removal and long-term control.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants (84). The combination may cause significant side effects, and it is not yet known if it will improve survival or cure rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Seventh People's Hospital of Chengdu
RECRUITINGChengdu, Sichuan, 610041, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
-
West China Shangjin Nanfu Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
-
West China Xiamen Hospital, Sichuan University
RECRUITINGXiamen, Fujian, China